SNSW(SH:688117)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was ¥117,392,501.03, representing a year-on-year increase of 26.33%[5] - Net profit attributable to shareholders decreased by 28.07% to ¥14,648,102.37 for the quarter[5] - The basic earnings per share for the quarter was ¥0.13, down 27.78% from the previous year[6] - Net profit for the third quarter of 2023 was ¥34,796,237.25, a decrease of 10.3% from ¥39,005,827.02 in the same quarter of 2022[22] - Basic and diluted earnings per share for the third quarter of 2023 were both ¥0.31, down from ¥0.35 in the same quarter of 2022[22] Research and Development - R&D investment totaled ¥10,256,904.65, an increase of 204.49% compared to the same period last year[6] - The proportion of R&D investment to revenue increased by 5.11 percentage points to 8.74%[6] - Research and development expenses for the first three quarters of 2023 totaled ¥20,381,012.27, compared to ¥18,831,772.17 in the same period of 2022, indicating an increase of 8.8%[20] Assets and Liabilities - Total assets increased by 17.68% to ¥1,303,894,555.46 compared to the end of the previous year[6] - As of September 30, 2023, the total assets of Chengdu Saintno Biotechnology Co., Ltd. amounted to CNY 1,303,894,555.46, an increase from CNY 1,108,008,638.28 at the end of 2022, reflecting a growth of approximately 17.6%[15] - The total liabilities as of the end of the third quarter of 2023 amounted to ¥462,266,573.99, compared to ¥281,271,366.55 at the end of the same period in 2022[18] - The total equity attributable to shareholders of the parent company was ¥841,627,981.47, an increase from ¥826,737,271.73 in the same period of 2022[18] Cash Flow - Cash flow from operating activities for the year-to-date was ¥30,945,700.40, a decrease of 17.59% compared to the previous year[5] - The net cash flow from operating activities for the first three quarters of 2023 was ¥30,945,700.40, down 17.6% from ¥37,550,693.41 in the first three quarters of 2022[24] - The cash inflow from investment activities in the first three quarters of 2023 was ¥271,438,776.87, a decrease of 38.8% from ¥443,879,190.79 in the same period of 2022[25] - The net cash flow from investment activities for the first three quarters of 2023 was -¥315,087,433.34, worsening from -¥101,847,619.14 in the first three quarters of 2022[25] - The cash inflow from financing activities in the first three quarters of 2023 was ¥216,695,833.33, compared to ¥100,000,000.00 in the same period of 2022[25] - The net cash flow from financing activities for the first three quarters of 2023 was ¥136,248,872.12, an increase of 85.0% from ¥73,604,546.54 in the first three quarters of 2022[25] Operational Highlights - The company recognized government subsidies amounting to ¥442,089.26 during the quarter, contributing to its financial performance[9] - The company is focusing on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[14] - The report does not indicate any significant mergers or acquisitions during the quarter, but strategic initiatives are being evaluated for future growth[14] - Total operating revenue for the first three quarters of 2023 reached ¥291,226,325.99, an increase of 11.5% compared to ¥260,431,862.58 in the same period of 2022[20] - Total operating costs for the first three quarters of 2023 were ¥254,711,696.95, up from ¥216,990,808.93 in 2022, reflecting a year-on-year increase of 17.4%[20]